Zhejiang Baiao Pharmaceutical Technology Co., Ltd.

To investigate whether there are differences in the extent and rate of absorption of the test preparation pimavanserin tartrate capsules (Zhejiang Biopharma Technology Co., Ltd., specification: 34 mg) and the reference preparation pimavanserin tartrate capsules (trade name: Nuplazid®, specification: 34 mg) after a single oral administration on an empty stomach or after a meal in healthy subjects, to evaluate the bioequivalence of the test preparation and the reference preparation when administered on an empty stomach or after a meal, and to observe the safety of the test preparation and the reference preparation in healthy subjects.